Jiangsu Cowin Biotech Co. Ltd. A
Jiangsu CoWin Biotech Co., Ltd. engages in the research and development, production, and sale of biological products in China. The company provides molecular diagnostic raw material enzymes, nucleic acid collection and protection agents, nucleic acid extraction and purification kits, molecular diagnostic testing reagents, etc. It also offers medical device products, nucleic acid collection and pr… Read more
Jiangsu Cowin Biotech Co. Ltd. A (688426) - Total Assets
Latest total assets as of June 2025: CN¥1.57 Billion CNY
Based on the latest financial reports, Jiangsu Cowin Biotech Co. Ltd. A (688426) holds total assets worth CN¥1.57 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jiangsu Cowin Biotech Co. Ltd. A - Total Assets Trend (2020–2024)
This chart illustrates how Jiangsu Cowin Biotech Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jiangsu Cowin Biotech Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Jiangsu Cowin Biotech Co. Ltd. A's total assets of CN¥1.57 Billion consist of 51.5% current assets and 48.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.8% |
| Accounts Receivable | CN¥41.66 Million | 2.6% |
| Inventory | CN¥45.87 Million | 2.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥49.97 Million | 3.1% |
| Goodwill | CN¥1.08 Million | 0.1% |
Asset Composition Trend (2020–2024)
This chart illustrates how Jiangsu Cowin Biotech Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Cowin Biotech Co. Ltd. A's current assets represent 51.5% of total assets in 2024, a decrease from 84.3% in 2020.
- Cash Position: Cash and equivalents constituted 15.8% of total assets in 2024, up from 8.2% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 3.1% of total assets.
Jiangsu Cowin Biotech Co. Ltd. A Competitors by Total Assets
Key competitors of Jiangsu Cowin Biotech Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Jiangsu Cowin Biotech Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Jiangsu Cowin Biotech Co. Ltd. A generates 0.08x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Jiangsu Cowin Biotech Co. Ltd. A is currently not profitable relative to its asset base.
Jiangsu Cowin Biotech Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.28 | 15.40 | 13.62 |
| Quick Ratio | 13.54 | 14.84 | 13.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.04 Billion | CN¥ 928.53 Million | CN¥ 1.34 Billion |
Jiangsu Cowin Biotech Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Jiangsu Cowin Biotech Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.99 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -11.2% |
| Total Assets | CN¥1.62 Billion |
| Market Capitalization | $108.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Cowin Biotech Co. Ltd. A's assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Jiangsu Cowin Biotech Co. Ltd. A's assets decreased by 11.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jiangsu Cowin Biotech Co. Ltd. A (2020–2024)
The table below shows the annual total assets of Jiangsu Cowin Biotech Co. Ltd. A from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.62 Billion | -11.20% |
| 2023-12-31 | CN¥1.82 Billion | -6.80% |
| 2022-12-31 | CN¥1.96 Billion | +201.38% |
| 2021-12-31 | CN¥648.77 Million | +37.57% |
| 2020-12-31 | CN¥471.60 Million | -- |